- Home
- ROOT vs TRVI Comparison
ROOT vs TRVI Comparison
Compare ROOT & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- TRVI
- Stock Information
- Founded
- ROOT 2015
- TRVI 2011
- Country
- ROOT United States
- TRVI United States
- Employees
- ROOT N/A
- TRVI N/A
- Industry
- ROOT Property-Casualty Insurers
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- ROOT Finance
- TRVI Health Care
- Exchange
- ROOT Nasdaq
- TRVI Nasdaq
- Market Cap
- ROOT 1.2B
- TRVI 1.4B
- IPO Year
- ROOT 2020
- TRVI 2019
- Fundamental
- Price
- ROOT $88.82
- TRVI $10.64
- Analyst Decision
- ROOT Buy
- TRVI Strong Buy
- Analyst Count
- ROOT 6
- TRVI 9
- Target Price
- ROOT $124.40
- TRVI $20.72
- AVG Volume (30 Days)
- ROOT 489.5K
- TRVI 1.6M
- Earning Date
- ROOT 11-05-2025
- TRVI 11-10-2025
- Dividend Yield
- ROOT N/A
- TRVI N/A
- EPS Growth
- ROOT N/A
- TRVI N/A
- EPS
- ROOT 3.34
- TRVI N/A
- Revenue
- ROOT $1,446,800,000.00
- TRVI N/A
- Revenue This Year
- ROOT $27.41
- TRVI N/A
- Revenue Next Year
- ROOT $9.74
- TRVI N/A
- P/E Ratio
- ROOT $26.57
- TRVI N/A
- Revenue Growth
- ROOT 38.50
- TRVI N/A
- 52 Week Low
- ROOT $68.48
- TRVI $2.36
- 52 Week High
- ROOT $181.14
- TRVI $11.83
- Technical
- Relative Strength Index (RSI)
- ROOT 58.91
- TRVI 55.52
- Support Level
- ROOT $77.50
- TRVI $10.30
- Resistance Level
- ROOT $82.50
- TRVI $11.82
- Average True Range (ATR)
- ROOT 3.95
- TRVI 0.55
- MACD
- ROOT 1.38
- TRVI -0.06
- Stochastic Oscillator
- ROOT 91.11
- TRVI 28.92
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.